Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879831 | 1.00 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8617206 | 0.88 | RAB9A (0.57) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Formic Acid Methyl Ester SCHEMBL27957057 | 0.88 | P4HTM (0.51) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6212230 | 0.84 | LMNA (0.50) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL18429796 | 0.82 | APP (0.64) | — | |
| Hydrochloric Acid SCHEMBL16758004 | 0.82 | CHRNB2 (0.41) | P4HTMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15633170 | 0.82 | APP (0.54) | MAOBRAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL2370266 | 0.82 | MAOB (0.63) | MAOBMAOANR4A2 | |
| SCHEMBL12854780 | 0.81 | APP (0.52) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8613941 | 0.81 | ALOX5 (0.59) | MAOBRAB9ASMN1; SMN2MAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4543848-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543857-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119546577-A | Modulators of G protein-coupled receptor 88 | 阿卡蒂亚药品公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119403782-A | Modulators of G protein-coupled receptor 88 | 阿卡蒂亚药品公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2009140163-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK & CO., INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| WO-2009046784-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1575586-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | Pfizer Japan Inc. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | P4HTM 1795/4885LMNA 4331/4885CYP1A2 168/4885 |
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | P4HTM 3719/4885LMNA 2607/4885CYP1A2 3406/4885 |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR84, GPR68 | P4HTM 2983/4885LMNA 4755/4885CYP1A2 2876/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | P4HTM 1795/4885LMNA 4331/4885CYP1A2 168/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | P4HTM 1523/4885LMNA 4410/4885CYP1A2 221/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | P4HTM 1268/4885LMNA 2487/4885CYP1A2 3656/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | P4HTM 4439/4885LMNA 4396/4885CYP1A2 4863/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | P4HTM 1899/4885LMNA 3232/4885CYP1A2 2215/4885 |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | P4HTM 1145/4885LMNA 4569/4885CYP1A2 1126/4885 |
| US-20250367158-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR68, HTR2A | P4HTM 2651/4885LMNA 4703/4885CYP1A2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.